PER
Click for more information
0.00% 8.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review

  1. Hot News
    193,110 Posts.
    lightbulb Created with Sketch. 2819
    clock Created with Sketch.
    26/06/17
    11:20
    Post #: 25487337

    June 26 (Reuters) - Antisense Therapeutics Ltd (ANP)

    • ATl1102 for multiple sclerosis (MS) phase IIB IND application has been submitted to US Food And Drug ADMINISTRATION (Fda) for its review
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

UNT UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off
right-arrow Created with Sketch.
SUM Summit Minerals jumps 6% as LiDAR survey boosts confidence in niobium mineralisation
right-arrow Created with Sketch.
MBK Metal Bank setting up shop in Saudi Arabia as part of MENA expansion plans
right-arrow Created with Sketch.
NEWS Want to talk crypto? Click here to join the discussion!
right-arrow Created with Sketch.
LU7 Filling the Lithium Conversion Gap: Lithium Universe commits to community collaboration through formation of joint committee for Bécancour
right-arrow Created with Sketch.
WR1 Stock watchers charged up by Winsome Resources' latest lithium drilling results
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $72.12M
Open High Low Value Volume
8.1¢ 8.1¢ 7.9¢ $142.6K 1.782M

Buyers (Bids)

No. Vol. Price($)
1 100000 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 1335 1
View Market Depth
Last trade - 16.10pm 20/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.